{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:40:04Z","timestamp":1751438404323,"version":"3.41.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":482,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Investigaci\u00f3n Cl\u00ednica"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.24875\/ric.23000274","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T21:12:39Z","timestamp":1715029959000},"page":"91-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Choices in Patients with Ph-Positive Chronic Myelogenous Leukemia In Mexico in the Era of Tyrosine Kinase Inhibitors: Stem Cell Transplantation or Tyrosine Kinase Inhibitors? Fifteen Years Later"],"prefix":"10.1016","volume":"76","author":[{"given":"Max","family":"Robles-Nasta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"S\u00e1nchez-Bonilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mois\u00e9s M.","family":"Gallardo-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar J.","family":"Hern\u00e1ndez-Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merittzel A.","family":"Montes-Robles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda de L.","family":"Pastel\u00edn-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Olivares-Gazca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo J.","family":"Ruiz-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo J.","family":"Ruiz-Arg\u00fcelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.24875\/RIC.23000274_bib1","series-title":"Fundamentos de Hematolog\u00eda","first-page":"159","article-title":"Leucemias cr\u00f3nicas","author":"G\u00f3mez Almaguer","year":"2021"},{"key":"10.24875\/RIC.23000274_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246269","article-title":"Potential to improve therapy of chronic myeloid leukemia (Cml), especially for patients with older age: incidence, mortality, and survival rates of patients with cml in Switzerland from 1995 to 2017","volume":"13","author":"Daskalakis","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.24875\/RIC.23000274_bib3","first-page":"192","article-title":"Aspectos actuales de la leucemia mieloide cr\u00f3nica","volume":"64","author":"Aguayo-Gonz\u00e1lez","year":"2012","journal-title":"Rev Investig Cl\u00edn"},{"key":"10.24875\/RIC.23000274_bib4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/10245332.2016.1182695","article-title":"The treatment of CML at an environment with limited resources","volume":"21","author":"G\u00f3mez-Almaguer","year":"2016","journal-title":"Hematology"},{"key":"10.24875\/RIC.23000274_bib5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/17474086.2017.1360180","article-title":"Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective","volume":"10","author":"Gomez-de-Le\u00f3n","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.24875\/RIC.23000274_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.24875\/RIC.23000274_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/bmt.2008.90","article-title":"Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?","volume":"42","author":"Ruiz-Arg\u00fcelles","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.24875\/RIC.23000274_bib8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/medethics-2021-107574","article-title":"Ethical analysis examining the prioritisation of living donor transplantation in times of healthcare rationing","volume":"49","author":"Kulkarni","year":"2022","journal-title":"J Med Ethics"},{"key":"10.24875\/RIC.23000274_bib9","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.24875\/RIC.23000274_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2009.05.002","article-title":"Current role of stem cell transplantation in chronic myeloid leukaemia","volume":"22","author":"Gratwohl","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.24875\/RIC.23000274_bib11","first-page":"141","article-title":"El programa de trasplantes de la cl\u00ednica ruiz de puebla: a 25 a\u00f1os de su creaci\u00f3n","volume":"19","author":"Murrieta-\u00c1lvarez","year":"2018","journal-title":"Rev Hematol"},{"key":"10.24875\/RIC.23000274_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/hematology.2022000329","article-title":"Transplantation in CML in the TKI era: who, when, and how ?","volume":"2022","author":"Niederwieser","year":"2022","journal-title":"Hematol Am Soc Hematal Educ Program"},{"key":"10.24875\/RIC.23000274_bib13","first-page":"235","article-title":"Molecular monitoring of the treatment of patients with BCR\/ABL (+) chronic myelogenous leukemia","volume":"53","author":"Ruiz-Arg\u00fcelles","year":"2001","journal-title":"Rev Invest Cl\u00edn M\u00e9x"},{"key":"10.24875\/RIC.23000274_bib14","first-page":"118","article-title":"Assessment of residual disease in acute leukemia by means of polymerase chain reaction: a prospective study in a single institution","volume":"52","author":"Ruiz-Arg\u00fcelles","year":"2000","journal-title":"Rev Invest Clin Mex"},{"key":"10.24875\/RIC.23000274_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.24875\/RIC.23000274_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"key":"10.24875\/RIC.23000274_bib17","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.clml.2011.03.028","article-title":"Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors","volume":"11","author":"Champlin","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.24875\/RIC.23000274_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.det.2019.05.014","article-title":"Review of graft-versus-host disease","volume":"37","author":"Ramachandran","year":"2019","journal-title":"Dermatol Clin"},{"key":"10.24875\/RIC.23000274_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12955-020-01651-2","article-title":"\u201cIs this the GVHD?\u201d A qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service","volume":"19","author":"De Vere Hunt","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"10.24875\/RIC.23000274_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023-common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.24875\/RIC.23000274_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ajh.26790","article-title":"Allogeneic transplantation for chronic myeloid leukemia: i\u2019m not dead yet!","volume":"98","author":"Radich","year":"2023","journal-title":"Am J Hematol"},{"key":"10.24875\/RIC.23000274_bib22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000351957","article-title":"Treating chronic myeloid leukemia in the era of tyrosine kinase inhibitors","volume":"130","author":"Gale","year":"2013","journal-title":"Acta Haematol"},{"key":"10.24875\/RIC.23000274_bib23","first-page":"306","article-title":"Perspectives in diagnosis and therapeutics in hematology","volume":"73","author":"Ruiz-Arg\u00fcelles","year":"2021","journal-title":"Rev Investig Cl\u00edn"}],"container-title":["Revista de Investigaci\u00f3n Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034837625001755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034837625001755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.clinicalandtranslationalinvestigation.com\/frame_esp.php?id=496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:11:01Z","timestamp":1751436661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034837625001755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0034837625001755"],"URL":"https:\/\/doi.org\/10.24875\/ric.23000274","relation":{},"ISSN":["0034-8376"],"issn-type":[{"type":"print","value":"0034-8376"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Choices in Patients with Ph-Positive Chronic Myelogenous Leukemia In Mexico in the Era of Tyrosine Kinase Inhibitors: Stem Cell Transplantation or Tyrosine Kinase Inhibitors? Fifteen Years Later","name":"articletitle","label":"Article Title"},{"value":"Revista de Investigaci\u00f3n Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.24875\/RIC.23000274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 Revista de Investigaci\u00f3n Cl\u00ednica. Published by Permanyer. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}